Table 1 Study characteristics, patient population

Han-Hwa Hu, 1993 [10]

CIS <50%: n = 84; CIS 50–74%: n = 23; CIS 75–99%: n = 17; CIS 100%: n = 8

Cross sectional study

n.r.

132

63

11%

2

2

1

1

Paivansalo,1999 [11]

both side CIS <80%: n = 46 ; at least one side CIS >80%:n = 48

Cross sectional study

n.r.

94

63.1

38%

2

2

1

1

Arai, 1998 [12]

DM without DRP: n = 27, DRP: n = 25

Cross sectional study

n.r.

52

DM without DRP: 50.0, DRP: 56.1

45%

1

2

1

3

Basturk, 2012 [13]

DM II without DRP: n = 40, DRP: n = 51, healthy subjects: n = 27

Cross sectional study

yes

118

DRP: 55.88, DM without DRP: 53.25, healthy subjects 53.59

DM without DRP: 45%, DRP: 49%; healthy controls: 48%

1

2

1

3

Jimenez-Aragon, 2013 [14]

Early glaucoma no-progression group: n = 59; early glaucoma progression group: n = 12

Longitudinal and prospective study

yes

71

No progression group 54.03, Progression group 55.75

No-Progression group: 59%; Progression group: 75%

1

1

1

3

Arsène, 2002 [18]

CRVO-ischaemic: n = 18; CRVO-non-ischaemic: n = 51; BRVO (ischaemic and non-ischaemic):n = 33

Longitudinal and prospective study

n.r.

102

61

38%

2

1

1

2

Tranquart, 1999 [19]

CRVO-ischemic: n = 18; CRVO: non-ischaemic: n = 51

Cross sectional study

n.r.

69

61 (based on 102 subjects)

38% (based on 102 subjects)

2

1

1

3

Plange, 1999 [17]

NTG: n = 62; healthy controls: n = 40

Cross-sectional study

yes

102

NTG: 57, healthy subjects: 58

37%

1

1

1

1

Martinez, 2005 [15]

POAG progression group: n = 23; POAG no-progression group: n = 26

Prospective cohort study

yes

49

63.7

53%

1

3

1

1

Suprasanna, 2014 [16]

POAG-progression group: n = 25; POAG no-progression-group: n = 53

Case control study

n.r.

78

62.6

41%

2

2

1

1

Williamson, 1994 [6]

CRVO without iris neovascularization: n = 22, CRVO with iris neovascularization: n = 8

Prospective cohort study

n.r.

30

67.2 (based on 80 patients)

49% (based on 80 subjects)

1

2

1

2